EMA Recommends Novo Nordisk Diabetes Drug for Marketing Approval

The European Medicines Agency’s Committee for Medicinal Products for Human Use said Friday that it is recommending Rybelus, a drug developed by Novo Nordisk A/S (NOVO-B.KO), as a treatment for type 2 diabetes.
The committee said this was the first oral glucagon-like peptide, or GLP-1, treatment to be recommended for this indication. This recently-developed class of drugs is a non-insulin medicine for type 2 diabetes which helps regulate insulin levels and has been shown to help achieve weight loss.
“We believe [Rybelus] has the potential to set a new standard for the treatment of type 2 diabetes in the EU,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk.
In most cases a recommendation by the CHMP leads to European marketing approval. Novo Nordisk said it expects to receive marketing authorization in the second quarter. The drug is already approved in the U.S.

https://www.marketscreener.com/NOVO-NORDISK-AS-1412980/news/Novo-Nordisk-EMA-Recommends-Novo-Nordisk-Diabetes-Drug-for-Marketing-Approval-29920377/